Für den Inhalt der Angaben zeichnet die Projektleitung verantwortlich.
This project, funded by Gebert Rüf Stiftung, is supported by the following project partners: ETH Zürich
Förderbeitrag: CHF 150'000
Dauer: 08.2020 - 02.2021
InnoBooster, seit 2018
Dept for Materials Science
8093 Zürich (Schweiz)
- alessandro.ofner@microcaps. ch
Making sure that drugs are released in the affected part of the body and at a specific rate is a huge challenge, because the size of the microcapsules that deliver these active ingredients is uncontrollable. At Microcaps we developed a patented technology that enables the size control of these microcapsules with Swiss precision, hence they all behave exactly the same. This means we can directly tailor and predict the release profile of a drug. Our solution is also highly relevant for fragrances, flavors and probiotics.
At Microcaps, an ETH spin off, we increased the throughput of perfectly size-controlled microencapsulation by a factor of 1000 compared to state-of-the-art methods. This allows for the first time to offer highest size control and industrial scales and therefore set a new gold standard to the microencapsulation market. Offering the highest precision, our customers can directly tailor and shape a release profile of their actives. Examples range from long-term treatment for injectable drugs, orally administered substances which need to survive the acidic environment of the stomach and release in the intestine, to inhalation carriers for an tailored uptake in the lungs.
Was ist das Besondere an diesem Projekt?
For many capsule systems, for example pharmaceutical treatments and cosmetics solution, the chemical composition of the microcapsule carrier is already well-defined and the materials are off-the-shelf product. However, there is a new evolving market, where we believe Microcaps to be a huge game-changer: the human microbiome. Probiotic delivery is currently massively attracting the attention of both industry and scientific research. Given the right microbial strains, is not only proven as treatment for obesity or our digestive health, it might also have medical impacts on several illnesses, e.g. respiratory infections, colics, even Altzheimer, and many more.
During our first PoC with a probiotic company and through several discussions and meetings with potential customers, we realized a need to improve our current development for a microcapsule system that can be loaded with any bacterial strain, is acidic resistent, and releases in the neutral environment of the intestine.
The starup Microcaps AG offers the new gold standard in microencapsulation and plans to sell its first equipment in 2021. The results of this Innobooster project will directly help to combine the probiotics market with Microcaps' current offering.
High-Throughput Step Emulsification for the Production of Functional Materials Using a Glass Microfluidic Device
; A. Ofner, D.G. Moore, P.A. Rühs, P. Schwendimann, M. Eggersdorfer, E. Amstad, D.A. Weitz & A.R. Studart, 2016, Macromolecular Chemistry and PhysicsControlled Massive Encapsulation via Tandem Step Emulsification in Glass
, Alessandro Ofner, Iacopo Mattich, Michael Hagander, Alessandro Dutto, Hansjörg Seybold, Patrick A. Rühs, André R. Studart, 2018, Advanced Functional Materials
Am Projekt beteiligte Personen
Letzte Aktualisierung dieser Projektdarstellung 29.07.2020